• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of regulatory cases referred to OFS that were reviewed within the timeframe given to OFS in the Case Management System (measures time in OFS only) in the month

Dictionary: Timely review of regulatory cases that come from the field is important as it allows FDA to take appropriate regulatory action such as issuance of a warning letter to the regulated industry. This can lead to a timely correction of problems in the industry resulting in a safer food supply.

Information is current as of December 31, 2013.

Fiscal Year - 2014

Skip graphic and jump to text data

TimeTargetPercentage
Oct 201380100
Nov 20138080
Dec 201380100
Jan 201480TBD
Feb 201480TBD
Mar 201480TBD
Apr 201480TBD
May 201480TBD
Jun 201480TBD
Jul 201480TBD
Aug 201480TBD
Sep 201480TBD

FY 2014 YTD: 91%

Total number of regulatory cases referred to OFS that were reviewed within the timeframe given to OFS in the Case Management System (measures time in OFS only) in the month

Fiscal Year - 2014
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2013N/A9
Nov 2013N/A16
Dec 2013N/A15
Jan 2014N/ATBD
Feb 2014N/ATBD
Mar 2014N/ATBD
Apr 2014N/ATBD
May 2014N/ATBD
Jun 2014N/ATBD
Jul 2014N/ATBD
Aug 2014N/ATBD
Sep 2014N/ATBD

FY 2014 YTD: 40

Total number of regulatory cases referred to OFS in the month that are due within the month

Fiscal Year - 2014
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2013N/A9
Nov 2013N/A20
Dec 2013N/A15
Jan 2014N/ATBD
Feb 2014N/ATBD
Mar 2014N/ATBD
Apr 2014N/ATBD
May 2014N/ATBD
Jun 2014N/ATBD
Jul 2014N/ATBD
Aug 2014N/ATBD
Sep 2014N/ATBD

FY 2014 YTD: 44

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.